Among 6 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Cytori Therapeutics had 11 analyst reports since August 8, 2015 according to SRatingsIntel. As per Friday, August 11, the company rating was maintained by Maxim Group. TH Capital maintained Cytori Therapeutics, Inc. (NASDAQ:CYTX) on Monday, August 10 with “Buy” rating. The stock has “Buy” rating by Maxim Group on Wednesday, May 31. B. Riley & Co downgraded the stock to “Neutral” rating in Tuesday, July 25 report. The stock of Cytori Therapeutics, Inc. (NASDAQ:CYTX) earned “Buy” rating by Maxim Group on Saturday, August 8. Maxim Group maintained Cytori Therapeutics, Inc. (NASDAQ:CYTX) on Monday, July 10 with “Buy” rating. The company was maintained on Monday, July 24 by Maxim Group. Zacks upgraded Cytori Therapeutics, Inc. (NASDAQ:CYTX) on Friday, September 4 to “Hold” rating. See Cytori Therapeutics, Inc. (NASDAQ:CYTX) latest ratings:
07/11/2017 Broker: FBR Capital Rating: Hold New Target: $0.5
11/08/2017 Broker: Maxim Group Rating: Buy New Target: $5.0000 Maintain
25/07/2017 Broker: B. Riley & Co Old Rating: Buy New Rating: Neutral Old Target: $5.75 Downgrade
24/07/2017 Broker: Maxim Group Rating: Buy New Target: $10.0000 Maintain
10/07/2017 Broker: Maxim Group Rating: Buy New Target: $10.0000 Maintain
The stock of Castlight Health, Inc. (NYSE:CSLT) is a huge mover today! It closed at $3.85 lastly. It is down 18.00% since December 8, 2016 and is downtrending. It has underperformed by 34.70% the S&P500.The move comes after 8 months negative chart setup for the $723.90M company. It was reported on Dec, 8 by Barchart.com. We have $3.73 PT which if reached, will make NYSE:CSLT worth $21.72M less.
Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions. The company has market cap of $8.96 million. The firm primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma. It currently has negative earnings. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.
The stock decreased 1.89% or $0.0049 during the last trading session, reaching $0.255. About 492,487 shares traded. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has declined 65.60% since December 8, 2016 and is downtrending. It has underperformed by 82.30% the S&P500.
Analysts await Castlight Health, Inc. (NYSE:CSLT) to report earnings on February, 21. They expect $-0.10 EPS, down 42.86% or $0.03 from last year’s $-0.07 per share. After $-0.09 actual EPS reported by Castlight Health, Inc. for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.
Castlight Health, Inc. operates a health benefits platform in the United States. The company has market cap of $723.90 million. The companyÂ’s platform engages employees to make better health decisions and enables employers to communicate and measure their benefit programs. It currently has negative earnings. The Company’s platform also provides real-time insight into employee engagement with benefits and programs enabling employers to monitor and adjust their strategies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.